UAE
Bahrain
Jordan
Kuwait
Oman
Qatar
Saudi ArabiaHealth News
New Data Demonstrate Treatment With 'Januvia®' (Sitagliptin) Reduces Hypoglycaemia In Elderly Populations
Date: Oct-03-2012New data announced at the 48th European Association for the Study of Diabetes (EASD) annual meeting show results of post-hoc pooled analysis of patients with type 2 diabetes aged 65 or older.[1] Those treated with 'Januvia®' (sitagliptin) 100 mg/day achieved similar blood sugar reductions as those treated with a sulphonylurea (SU), with significantly less hypoglycaemia (low blood sugar).[1] Nearly a third (28.2%) of patients taking an SU experienced hypoglycaemia compared with just 6% of those treated with sitagliptin, a DPP-4 inhibitor licensed for the treatment of type 2 diabetes...
Tuna Report Solves Problem That Doesn't Exist
Date: Oct-03-2012A recent report from The Mercury Policy Project features a dozen solutions for the alleged problem that kids eat too much tuna. As a dietitian, I had the same reaction to this as if I had read "kids are eating too many fruits and vegetables" or "kids are playing outside too much". Tuna, like other ocean fish, is a nutrition powerhouse. A single serving packs lean protein and omega-3s, both essential for normal development, into less than 150 calories. And as an added bonus, tuna is convenient, widely available, and affordable...
Teen Drinking And Driving Drops 54% In 20 Years
Date: Oct-03-2012Ten percent of teenagers today say they drove while under the influence of alcohol during the preceding 30 days, compared to 22% in 1991; a drop of 54%, says a Vital Signs study published by the CDC (Centers for Disease Control and Prevention). Although this is welcome news, nearly one million teenagers (aged 16+) drove under the influence of alcohol in 2011. A teenager has a threefold higher risk of being involved in a fatal car crash than an adult, the authors wrote...
Beta-Blockers Are Not So Great
Date: Oct-03-2012Beta-blockers, one of the most frequently prescribed drugs for heart disease, may not be as effective for certain patients as experts had thought, researchers from the NYU School of Medicine, New York, reported in JAMA (Journal of the American Medical Association). Beta-blockers are known to help people with badly damaged hearts caused by heart attacks, as well as patients with heart failure...
HPV4 Vaccine Is Safe For Girls And Young Women
Date: Oct-03-2012The HPV4 vaccine, Gardasil, is safe for adolescent girls and young women in routine clinical care, researchers from the Kaiser Permanente Vaccine Study Center in Oakland, California, reported in Archives of Pediatrics and Adolescent Medicine. The vaccine is linked to a slight risk of same-day fainting (syncope) as well as skin infections within two weeks. The researchers said that their findings provide further compelling evidence of the HPV4's general safety for routine use in a clinical care setting for the prevention of cervical cancer as well as other reproductive and genital cancers...
Renal Cell Carcinoma Phase III Data
Date: Oct-03-2012New trial results on pazopanib and temsirolimus have important implications for patients New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes (tubules) in the kidney...
Breast Cancer Patients Live Nearly Six Months Longer With New Precision Drug Compared To Current Treatment Option
Date: Oct-03-2012Data from the Phase III EMILIA study, presented at the European Society for Medical Oncology (ESMO) show that T-DM1 (trastuzumab emtansine) prolongs the lives of patients with advanced HER2-positive breast cancer when compared with the only approved licensed treatment combination, lapatinib and capecitabine, (30.9 months vs. 25.1 months, HR=0.682; P=0.0006), while significantly reducing the side effects of chemotherapy.1 T-DM1 is expected to gain a licence for use in the UK late 2013...
Potential New Class Of Drugs Protects Nerve Cells In Models Of Parkinson's Disease And ALS
Date: Oct-03-2012Diseases that progressively destroy nerve cells in the brain or spinal cord, such as Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), are devastating conditions with no cures. Now, a team that includes a University of Iowa researcher has identified a new class of small molecules, called the P7C3 series, which block cell death in animal models of these forms of neurodegenerative disease. The P7C3 series could be a starting point for developing drugs that might help treat patients with these diseases. These findings are reported in two new studies published the week of Oct...
Rheumatoid Arthritis Tied To Raised Risk Of Blood Clots
Date: Oct-03-2012A new study from Sweden suggests that patients with rheumatoid arthritis may be at higher risk for blood clots in the first ten years after diagnosis compared to the general population. But while admission to hospital was also a risk factor for blood clots in such patients, Marie Holmqvist of the Karolinska Institute in Stockholm, and colleagues, found this to be no greater than it was for the general population...
The Challenges Of Managing Blood Clotting In Cancer Patients
Date: Oct-03-2012New findings that highlight the challenges of managing thromboembolic events in patients being treated for cancer were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. Venous thromboembolism causes symptoms in about 3 to 4% of cancer patients whose chemotherapy drugs are delivered via a central venous catheter, comments Dr. Fausto Roila, from Medical Oncology Department, Terni, Italy, Chair of the ESMO 2012 Supportive Care Track...
Stay Connected
